SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK 2003 Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95: 12761299.
  • 2
    Yoshino I, Yohena T, Kitajima M, Ushijima C, Nishioka K, Ichinose Y, Sugimachi K 2001 Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs. Ann Thorac Cardiovasc Surg 7: 204209.
  • 3
    Schmitt JM, Hwang K, Winn SR, Hollinger JO 1999 Bone morphogenetic proteins: An update on basic biology and clinical relevance. J Orthop Res 17: 269278.
  • 4
    Feeley BT, Gamradt SC, Hsu WK, Krenek L, Liu N, Robbins P, Huard J, Lieberman JR 2005 Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 20: 21892199.
  • 5
    Dai J, Kitagawa Y, Zhang J, Yao Z, Mizokami A, Cheng S, Nor J, McCauley LK, Taichman RS, Keller ET 2004 Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 64: 994999.
  • 6
    Feeley BT, Krenek L, Liu NQ, Hsu WK, Gamradt S, Schwarz E, Huard J, Lieberman JR 2005 Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 20: 21892199.
  • 7
    Schwalbe M, Sanger J, Eggers R, Naumann A, Schmidt A, Hoffken K, Clement JH 2003 Differential expression and regulation of bone morphogenetic protein 7 in breast cancer. Int J Oncol 23: 8995.
  • 8
    Gobbi G, Sangiorgi L, Lenzi L, Casadei R, Canaider S, Strippoli P, Lucarelli E, Ghedini I, Donati D, Fabbri N, Warzecha J, Yeoung C, Helman LJ, Picci P, Carinci P 2002 Seven BMPs and all their receptors are simultaneously expressed in osteosarcoma cells. Int J Oncol 20: 143147.
  • 9
    Sulzbacher I, Birner P, Trieb K, Pichlbauer E, Lang S 2002 The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter. J Clin Pathol 55: 381385.
  • 10
    Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T, Terada M 1997 Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 57: 50225027.
  • 11
    Masuda H, Fukabori Y, Nakano K, Takezawa Y, Csuzuki T, Yamanaka H 2003 Increased expression of bone morphogenetic protein-7 in bone metastatic prostate cancer. Prostate 54: 268274.
  • 12
    Langenfeld EM, Bojnowski J, Perone J, Langenfeld J 2005 Expression of bone morphogenetic proteins in human lung carcinomas. Ann Thorac Surg 80: 10281032.
  • 13
    Langenfeld EM, Calvano SE, Lowry SF, Amenta P, Langenfeld J 2003 The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 24: 14451454.
  • 14
    Langenfeld EM, Langenfeld J 2004 Bone morphogenetic protein-2 stimulates angiogenesis in developing tumors. Mol Cancer Res 2: 141149.
  • 15
    Yin JJ, Pollock CB, Kelly K 2005 Mechanisms of cancer metastasis to the bone. Cell Res 15: 5762.
  • 16
    Brown JM, Zhang J, Keller ET 2004 Opg, RANKl, and RANK in cancer metastasis: Expression and regulation. Cancer Treat Res 118: 149172.
  • 17
    Wittrant Y, Theoleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, Redini F 2004 RANKL/RANK/OPG: New therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 1704: 4957.
  • 18
    Kitazawa S, Kitazawa R 2002 RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198: 228236.
  • 19
    Whang PG, Schwarz EM, Gamradt SC, Dougall W, Lieberman JR 2005 The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res 23: 14751483.
  • 20
    Zhang D, Schwarz EM, Rosier RN, Zuscik MJ, Puzas JE, O'Keefe RJ 2003 ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development. J Bone Miner Res 18: 15931604.
  • 21
    Sordillo EM, Pearse RN 2003 RANK-Fc: A therapeutic antagonist for RANK-L in myeloma. Cancer 97(3 Suppl): 802812.
  • 22
    Lee Y, Schwarz E, Davies M, Jo M, Gates J, Wu J, Zhang X, Lieberman JR 2003 Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. J Orthop Res 21: 6272.
  • 23
    Lee YP, Schwarz EM, Davies M, Jo M, Gates J, Zhang X, Wu J, Lieberman JR 2002 Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 62: 55645570.
  • 24
    Nelson JB, Nguyen SH, Wu-Wong JR, Opgenorth TJ, Dixon DB, Chung LW, Inoue N 1999 New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 53: 10631069.
  • 25
    Guise TA, Yin JJ, Mohammad KS 2003 Role of endothelin-1 in osteoblastic bone metastases. Cancer 97(3 Suppl): 779784.
  • 26
    Doherty A, Smith G, Banks L, Christmas T, Epstein RJ 1999 Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer: Implications for paracrine growth. J Pathol 188: 278281.
  • 27
    Goltzman D 1997 Mechanisms of the development of osteoblastic metastases. Cancer 80(8 Suppl): 15811587.
  • 28
    Zhang J, Dai J, Yao Z, Lu Y, Dougall W, Keller ET 2003 Solbule receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 63: 78837890.
  • 29
    Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O'Keefe RJ, Boyce BF, Schwarz EM 2002 In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res 17: 192199.
  • 30
    Oyajobi BO, Mundy GR 2003 Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: Novel therapeutic targets in myeloma. Cancer 97(3 Suppl): 813817.
  • 31
    Angelucci A, Gravina GL, Rucci N, Festuccia C, Muzi P, Vicentini C, Teti A, Bologna M 2004 Evaluation of metastatic potential in prostate carcinoma: An in vivo model. Int J Oncol 25: 17131720.
  • 32
    Peng H, Chen ST, Wergedal JE, Polo JM, Yee JK, Lau KH, Baylink DJ 2001 Development of an MFG-based retroviral vector system for secretion of high levels of functionally active human BMP4. Mol Ther 4: 95104.
  • 33
    Peng H, Wright V, Usas A, Gearhart B, Shen HC, Cummins J, Huard J 2002 Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 110: 751759.
  • 34
    Hannallah D, Peng H, Young B, Usas A, Gearhart B, Huard J 2004 Retroviral delivery of Noggin inhibits the formation of heterotopic ossification induced by BMP-4, demineralized bone matrix, and trauma in an animal model. J Bone Joint Surg Am 86: 8091.
  • 35
    Gamradt SC, Feeley BT, Liu NQ, Roostaeian J, Schwarz EM, Huard J, Lieberman JR 2004 The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone. Anticancer Res 25: 107115.
  • 36
    Uy HL, Mundy GR, Boyce BF, Story BM, Dunstan CR, Yin JJ, Roodman GD, Guise TA 1997 Tumor necrosis factor enhances parathyroid hormone-related protein-induced hypercalcemia and bone resorption without inhibiting bone formation in vivo. Cancer Res 57: 31943199.
  • 37
    Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL 2005 Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 65: 17101718.
  • 38
    Pfetzenmaier J, Quinn JE, Odman AM, Zhang J, Keller ET, Vessella RL, Corey E 2003 Characterization of C4–2 prostate cancer bone metastases and their response to castration. J Bone Miner Res 18: 18821888.
  • 39
    Hastings RH, Burton DW, Summers-Torres D, Quintana R, Biederman E, Deftos LJ 2000 Splenic, thymic, bony and lymph node metastases from orthotopic human lung carcinomas in immunocompromised mice. Anticancer Res 20: 36253629.
  • 40
    Bendre MS, Margulies AG, Walser B, Akel NS, Bhattacharrya S, Skinner RA, Swain F, Ramani V, Mohammad KS, Wessner LL, Martinez A, Guise TA, Chirgwin JM, Gaddy D, Suva LJ 2005 Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res 65: 1100111009.
  • 41
    Arnold SF, Tims E, McGrath BE 1999 Identification of bone morphogenetic proteins and their receptors in human breast cancer cell lines: Importance of BMP2. Cytokine 11: 10311037.
  • 42
    Wen XZ, Miyake S, Akiyama Y, Yuasa Y 2004 BMP-2 modulates the proliferation and differentiation of normal and cancerous gastric cells. Biochem Biophys Res Commun 316: 100106.
  • 43
    Pouliot F, Blais A, Labrie C 2003 Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Res 63: 277281.
  • 44
    Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, Kwiatkowski W, Affolter M, Vale WW, Belmonte JC, Choe S 2002 Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 420: 636642.
  • 45
    Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, Kwiatkowski W, Baban K, Affolter M, Vale WW, Belmonte JC, Choe S 2003 Structural basis of BMP signaling inhibition by Noggin, a novel twelve-membered cystine knot protein. J Bone Joint Surg Am 85(Suppl 3): 5258.
  • 46
    Kleeff J, Maruyama H, Ishiwata T, Sawhney H, Friess H, Buchler MW, Korc M 1999 Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 116: 12021216.
  • 47
    Koide M, Murase Y, Yamato K, Noguchi T, Okahashi N, Nishihara T 1999 Bone morphogenetic protein-2 enchances ostetoclast formation mediated by interleukin-1 alpha through upregulation of osteoclast differentiation factor and cyclooxygenase-2. Biochem Biophys Res Commun 259: 97102.
  • 48
    O'Keefe RJ, Guise TA 2003 Molecular mechanisms of bone metastasis and therapeutic implications. Clin Orthop 415(Suppl): S100S104.
  • 49
    Tripathy D, Lichinitzer M, Lazarev A, Apffelstaedt J, Budde M, Bergstrom B, Group MS 2004 Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 15: 743750.
  • 50
    Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D 2005 Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: A randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92: 18691876.
  • 51
    Saad F 2002 Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 1: 145152.
  • 52
    Rodrigues P, Hering F, Campagnari JC 2004 Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients. Prostate Cancer Prostatic Dis 7: 350354.